[HTML][HTML] Dapagliflozin impact on the exercise capacity of non-diabetic heart failure with reduced ejection fraction patients
J Reis, AR Teixeira, AV Gonçalves, RI Moreira… - Journal of Clinical …, 2022 - mdpi.com
Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients.
J Reis, AR Teixeira, AV Gonçalves… - Journal of Clinical …, 2022 - europepmc.org
Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
[PDF][PDF] Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
J Reis, AR Teixeira, AV Gonçalves, RI Moreira… - J. Clin. Med, 2022 - core.ac.uk
Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
J Reis, AR Teixeira, AV Gonçalves… - Journal of clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
J Reis, AR Teixeira, AV Gonçalves… - Journal of Clinical …, 2022 - search.proquest.com
Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
[HTML][HTML] Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
J Reis, AR Teixeira, AV Gonçalves… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients.
J Reis, AR Teixeira, AV Gonçalves… - Journal of Clinical …, 2022 - search.ebscohost.com
Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients.
J Reis, AR Teixeira, AV Gonçalves… - Journal of Clinical …, 2022 - europepmc.org
Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …